Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Myelodysplastic Syndromes 87Leukemia, Myelogenous, Chronic, BCR-ABL Positive 71Leukemia, Myeloid, Acute 66Leukemia 64Myeloproliferative Disorders 60Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Primary Myelofibrosis 39Leukemia, Myeloid, Chronic-Phase 39Leukemia, Myelomonocytic, Chronic 38Polycythemia Vera 32Lymphoma, Non-Hodgkin 29Lymphoma 29Multiple Myeloma 28Leukemia, Lymphocytic, Chronic, B-Cell 28Hodgkin Disease 27Lymphoma, Large B-Cell, Diffuse 26Lymphoma, Mantle-Cell 25Burkitt Lymphoma 25Leukemia, Myeloid, Accelerated Phase 24Lymphoma, Large-Cell, Immunoblastic 23Lymphoma, Follicular 23Lymphoma, B-Cell, Marginal Zone 23Blast Crisis 23Thrombocythemia, Essential 20Lymphoma, T-Cell, Cutaneous 19Leukemia, Hairy Cell 18Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 17Anemia, Refractory, with Excess of Blasts 17Neoplasms, Plasma Cell 16Myelodysplastic-Myeloproliferative Diseases 16

Interventions

luspatercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × beta-Thalassemia × Myeloid × Clear all
NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡